Orum Therapeutics announces extraordinary shareholder meeting
Bitget2026/10/08 09:33Orum Therapeutics will hold an extraordinary shareholder meeting on Oct. 23, 2026 in Daejeon, South Korea. Shareholders will vote on appointing Geoffrey Harris Meyerson as a non-executive director. Vote scheduled on appointing Peter Unnam Park as an independent director. Resolutions include granting stock options, ratifying previously granted stock options, and amending the articles of incorporation. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Orum Therapeutics Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261008000653), on October 08, 2026, and is solely responsible for the information contained therein.
- Orum Therapeutics will hold an extraordinary shareholder meeting on Oct. 23, 2026 in Daejeon, South Korea.
- Shareholders will vote on appointing Geoffrey Harris Meyerson as a non-executive director.
- Vote scheduled on appointing Peter Unnam Park as an independent director.
- Resolutions include granting stock options, ratifying previously granted stock options, and amending the articles of incorporation.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Google (GOOGL.US) warns that new Australian cybersecurity regulations may cut off minors' access to Gmail
Google stated that a new cybersecurity bill in Australia could prevent minors from using Gmail.

Canaccord Genuity: Lowers Oklo's target price to $66

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
